Goldman Sachs Initiates Coverage On Regeneron Pharmaceuticals with Buy Rating, Announces Price Target of $824
Goldman Sachs analyst Salveen Richter initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy rating and announces Price Target of $824.